Delivery Order SPE2DB22D3301-SPE2DB25FZ1DN
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,621.24 for Zepbound 5 mg/0.5 mL pens on August 4, 2025, with completion scheduled for August 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist indicated for weight management, representing the...
- The Defense Logistics Agency awarded a $1,525.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 mL pen injectors on September 3, 2025, with completion expected by September 4, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The order will be...
- The Defense Logistics Agency awarded a delivery order valued at $1,596.72 to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 mL pens on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price delivery order was issued without set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania location. Zepbound is a tirzepatide injection used for weight management and represents one of numerous pharmaceutical products...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Zepbound 10 mg/0.5 ml pens in 0.5 ml quantities, valued at $14,093.41. This firm fixed-price delivery order, with an ultimate completion date of August 20, 2025, represents a competitively awarded contract with no set-aside designation. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $19,897.15 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on September 10, 2025, with an ultimate completion date of September 11, 2025. This competitively awarded, firm fixed-price delivery order was issued without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist medication used...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pens valued at $14,691.86. This firm fixed-price delivery order, issued on August 13, 2025, with completion expected by August 14, 2025, represents a routine pharmaceutical procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime contract vehicle running through December 2026....
- The Defense Logistics Agency awarded a $1,143.87 delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pens on July 18, 2025, with completion targeted for July 21, 2025. This firm fixed-price contract represents a competitively awarded, non-set-aside procurement executed by the prime contractor's corporate office located in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $1,906.45 delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pen injectors on August 18, 2025. This non-competitive delivery order represents a firm fixed price transaction with a performance completion date of August 19, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $5,918.72 firm fixed price delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pen injections on June 2, 2025, with an ultimate completion date of June 3, 2025. This competitive, non-set-aside award was issued from AmerisourceBergen's Conshohocken, Pennsylvania location and represents a single delivery order under the company's larger contract vehicle with DLA. Zepbound (tirzepatide) is a GLP-1 receptor agonist used for weight management...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections with a ceiling value of $2,669.03. This is a firm fixed-price delivery order with an ultimate completion date of August 18, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical federal vendor for military and veteran...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FZ1DNDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $7,076.05 to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pens on September 17, 2025, with completion targeted for September 18, 2025. The contract utilizes firm fixed price pricing with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion pharmaceutical support vehicle extending through December 2026 that enables supply of medications and medical commodities to support military healthcare programs globally. Zepbound (tirzepatide) is a GLP-1 receptor agonist indicated for weight management and represents the type of specialty pharmaceutical products within AmerisourceBergen Drug Corp's extensive federal contract portfolio. As a major pharmaceutical distributor serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems, the company maintains consistent delivery order activity across diverse therapeutic domains. The company's demonstrated capability to meet federal procurement requirements through open competition, combined with its scale as a critical vendor for military and veteran healthcare supply chains, positions it as a primary supplier under the DLA's pharmaceutical procurement framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.1k | 9/17/25 |